Prostate Cancer

While unlikely to add significant amounts to Taxotere’s total sales, high uptake in niche indications will help the drug maintain its blockbuster status.Indeed, given that Bristol-Myers Squibb is not undertaking further expansion of indications for Taxol, Taxotere is presented with the opportunity to remain the standard therapy in numerous indications.

RELATED NEWS Sanofi-Aventis: strong sales before generics gloom2 Feb 2006 Aventis extends research collaboration with ImmunoGen1 Sep 2005 Sanofi-Aventis/BMS: a Plavix plague on both their houses?

27 Jan 2006 Sanofi-Aventis: Taxotere sales set for modest boost5 Dec 2005 Court approves delay in Plavix patent infringement suit 11 May 2005 COMPANIES MENTIONED Bristol-Myers Squibb Company General Electric Company YOUR OPINION...

Comment on this Article back to top BUSINESS REVIEW SITES: Food Auto ©2006 Business Review Ltd ...

Read more...